Autumn
AI in automation
AI has enormous potential in drug research and the life sciences. Investors have recognised this. Almost half of the US$165 billion raised for AI companies in the first half of 2025 went into this sector.
In this Focus:
- Big Bang in AI drug development
- Pretrained generative AI enters pharmacology
- Pancreatic cancer: Screening test
- Sepsis diagnosis: culture-free, rapid and non-invasive
- News from SLAS Association
The Focus is part of European Biotechnology Magazine Autumn 2025.
